The FDA has provided clearance for Medtronic's Vanta, a recharge free implantable neurostimulator.
Vanta has a battery life of up to 11 years, offering almost twice the device life of competitive primary cell devices, the company said in a June 10 news release.
The device includes Medtronic's SureScan technology, which provides full-body MRI access, and AdaptiveStim allows for automatic adjusting stimulation to maintain each patient's optimal dose.
"The extended battery life, broad MRI compatibility and personalized relief through AdaptiveStim technology allow for a more hassle-free experience and greater freedom for my patients as we manage their chronic pain," said Krishnan Chakravarthy, MD, PhD, a San Diego-based interventional pain management physician.
Vanta also features Snapshot, a data insights system that records patient activity levels to facilitate objective health conversations with clinicians.